Showing 2661-2670 of 5909 results for "".
- JCRS Publishes Phase 2 Nepafenac Clinical Trial With Evolute Sustained Drug Delivery Systemhttps://modernod.com/news/jcrs-publishes-phase-2-nepafenac-clinical-trial-with-evolute-sustained-drug-delivery-system/2478843/Mati Therapeutics announced that a peer reviewed manuscript of a phase 2 clinical trial evaluating the safety and efficacy of Nepafenac delivered via Mati’s proprietary Evolute sustained ocular drug delivery platform has been published in the February Journal of Cataract and Refractive Surgery
- Gemini Therapeutics Debuts as Publicly Traded Company Focused on Age-Related Macular Degenerationhttps://modernod.com/news/gemini-therapeutics-debuts-as-publicly-traded-company-focused-on-age-related-macular-degeneration/2478841/Gemini Therapeutics announced the completion of its business combination with FS Development Corp., a special purpose acquisition company (SPAC) sponsored by Foresite Capital. Gemini Therapeutics, the resulting combined company, will commence trading its shares today on the Nasdaq Global Market u
- Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Designhttps://modernod.com/news/aldeyra-therapeutics-announces-phase-3-tranquility-dry-eye-disease-trial-design/2478835/Aldeyra Therapeutics announced the finalization of the design of the phase 3 TRANQUILITY trial of 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease. Consistent with previously announced results from the run-in cohort of TRANQUILITY, ocular redness over 90 minutes in a dry
- GSK, CureVac Partner to Develop mRNA Vaccines for COVID-19 Variantshttps://modernod.com/news/gsk-curevac-partner-to-develop-mrna-vaccines-for-covid-19-variants/2478831/GlaxoSmithKline entered into a new collaboration with CureVac to develop a multi-valent mRNA candidate vaccine to address multiple emerging variants of COVID-19, the companies announced Wednesday. “We believe that next-generation vaccines will be crucial in the continued fight against COVID
- Jazz to Buy Cannabinoid Drugmaker GW Pharma in $7.2-Billion Dealhttps://modernod.com/news/jazz-to-buy-cannabinoid-drugmaker-gw-pharma-vva-7-2-billion-deal/2478832/Jazz Pharmaceuticals entered into a definitive agreement to acquire GW Pharmaceuticals for $220 per share, or a total consideration of $7.2 billion, adding the latter’s cannabinoid product platform, including Epidiolex (cannabidiol), to its neuroscience pipeline, the companies announced Wed
- NeuroVision Imaging Receives Funding From the ADDF to Develop Biomarkers to Diagnose Alzheimer’s and Related Dementiashttps://modernod.com/news/neurovision-imaging-receives-funding-from-the-addf-to-develop-biomarkers-to-diagnose-alzheimers-and-related-dementias/2478823/NeuroVision Imaging announced it has received an investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to support developing reliable, affordable biomarker tests for Alzheimer’s disease and other forms of dementia and neurodegenerative disorders. “Many of the existing diagnostic
- Lensar Expands Board of Directors with the Appointments of Aimee S. Weisner and Elizabeth G. O’Farrellhttps://modernod.com/news/lensar-expands-board-of-directors-with-the-appointments-of-aimee-s-weisner-and-elizabeth-g-ofarrell/2478817/Lensar announced the expansion of its board of directors to seven members with the appointments of Aimee S. Weisner and Elizabeth G. O’Farrell, effective February 1, 2021. In addition to serving on the company’s Board of Directors, Ms. Weisner will
- Leo Lens Pharma Announces Corporate Name Change to MediPrint Ophthalmicshttps://modernod.com/news/leo-lens-pharma-announces-corporate-name-change-to-mediprint-ophthalmics/2478794/Leo Lens Pharma has announced a corporate name change to MediPrint Ophthalmics, effective immediately. The company also announced it has successfully closed an over-subscribed Seed round fundraising. The company’s rebranding to MediPrint Ophthalmics is based on input from stakeholders and
- MeiraGTx Announces AAV-CNGA3 Granted Fast Track Designation by FDA for Treatment of Achromatopsiahttps://modernod.com/news/meiragtx-announces-aav-cnga3-granted-fast-track-designation-by-fda-for-treatment-of-achromatopsia/2478795/MeiraGTx Holdings announced that the FDA has granted Fast Track designation to its AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia (ACHM) caused by mutations in the CNGA3 gene. ACHM is an inherited retinal disease that severely limits a per
- Keeler Partners With Merakris Therapeutics, Developer of Biological Barrier Grafthttps://modernod.com/news/keeler-patners-with-merakris-therapeutics-developer-of-biological-barrier-graft/2478785/Keeler has announced its partnership with Merakris Therapeutics, which is developing commercially scalable biotherapeutic technologies derived from stem cells that promote homeostasis in damaged tissue. Terms of the deal were not disclosed. “We are excited. This partnership accelera